Взаимосвязь метаболически ассоцированной стеатозной болезни печени и ишемической болезни сердца: клинические аспекты коморбидности

Background. To investigate the association between metabolically associated steatotic liver disease (MASLD) and ischemic heart disease (IHD), focusing on the clinical aspects of their comorbidity. Materials and methods. Data from 110 patients with IHD were analyzed. MASLD was diagnosed using liver ultrasound and metabolic parameters. Correlation and regression analyses were conducted to evaluate the relationship between metabolic disturbances and IHD severity. Results. MASLD was identified in 77.3% of patients with IHD. The severity of liver steatosis correlated with C-reactive protein levels, HOMA-IR index, and the frequency of acute coronary events. Patients with severe steatosis were more likely to experience myocardial infarction and dyslipidemia. Conclusion. MASLD is a significant risk factor that exacerbates the course of IHD. Early diagnosis and correction of metabolic disorders are essential for improving the prognosis of patients with this comorbidity.